How new avelumab data add to knowledge of treatment’s use as maintenance therapy
June 16th 2021“I think the data from this particular abstract pretty much reinforce that if you get avelumab as maintenance therapy, the time that patients spend in first- and second-line therapy is prolonged compared to patients who get best supportive care,” says Petros Grivas, MD, PhD.
Urologist discusses overcoming telemedicine barriers
June 15th 2021“A lot of medicine that you do in person is very provider-centric in the sense that you tend to just walk from room to room and see patients, whereas with virtual care, you need to change the workflow a little bit,” says Chad Ellimoottil, MD, MS.
Clinical and regulatory implications of KEYNOTE-564 trial of adjuvant pembrolizumab in RCC
June 12th 2021Toni K. Choueiri, MD, discusses the clinical and regulatory implications of the phase 3 KEYNOTE-564 trial, which explored pembrolizumab following nephrectomy in patients with clear cell renal cell carcinoma.
Study backs increased PSA screening for younger African Americans
June 9th 2021In this video, lead author Edmund M. Qiao discusses study results presented during the 2021 ASCO Annual Meeting which showed an association between increased prostate-specific antigen screening and improved outcomes in younger African American patients.
Study compares genomic profiling in patients with prostate cancer of African, European ancestry
June 9th 2021“Patients of African ancestry were actually less likely to receive comprehensive genomic profiling earlier in their treatment course than patients of European ancestry, and…patients of African ancestry [were] less likely to be treated in clinical trials,” says Jessica Lee, MS.
Dr. Galsky on the “new dawn” in bladder-sparing in bladder cancer
June 7th 2021“It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really have the community embrace this as a reasonable option for patients with bladder cancer,” says Matthew Galsky, MD.